ArticlemSphere2021
High Seropositivity Rate of Neutralizing Antibodies to Astrovirus VA1 in Human Populations.
Article in mSphere, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 20 citations in OpenAlex.
- Structure of the human astrovirus capsid spike in complex with the neonatal Fc receptor.Nature communications · 2025Article
- Comparison of classic and novel human astrovirus MLB and VA seroprevalence in HIV and non-HIV cohorts in South China demonstrates high seroreactivity to classic human astrovirus, which is associated with HIV infection.Microbiology spectrum · 2025Article
- Novel murine model of human astrovirus infection reveals cardiovascular tropismJournal of virology · 2025Article
- Computational design of a glycosylated multi-epitope vaccine against HAsV-1 and HAsV-2 astrovirus for acute gastroenteritis.Scientific reports · 2025Article
- The neonatal Fc receptor is a cellular receptor for human astrovirus.Nature microbiology · 2024Article
- Mouse and human immune responses share neutralization epitopes of HAstV-VA1.Journal of virology · 2024Article
- Structure and antigenicity of the divergent human astrovirus VA1 capsid spike.PLoS pathogens · 2024Article
- Acute gastroenteritis outbreaks caused by human astrovirus, 1978-2021: A systematic review.Biosafety and health · 2023Review
- Detection and Characterization of Goose Astrovirus Infections in Hatcheries and Commercial Goose Flocks.Transboundary and emerging diseases · 2023Article
- Structure of the divergent human astrovirus MLB capsid spike.Structure (London, England : 1993) · 2022Article
- The Capsid Precursor Protein of Astrovirus VA1 Is Proteolytically Processed Intracellularly.Journal of virology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 3 countries.
Funding
Abstract
Astroviruses are common pathogens of the human gastrointestinal tract, but they have been recently identified from cases of fatal meningoencephalitis. Astrovirus VA1 is the most frequently detected astrovirus genotype from cases of human encephalitis, but the prevalence of neutralizing antibodies to VA1 in human sera is unknown. We developed a focus reduction neutralization assay (FRNT) for VA1 and measured the seroprevalence of neutralizing antibodies from two cohorts of adult and pediatric serum samples: (i) an age-stratified cohort from St. Louis, MO, collected from 2007 to 2008 and (ii) a cohort from the Peruvian Amazonian River Basin collected in the late 1990s. In the St. Louis cohort, the lowest seropositivity rate was in children 1 year of age (6.9%), rising to 63.3% by ages 9 to 12, and 76.3% of adults ≥20 years were positive. The Peruvian Amazon cohort showed similar seropositivity rates across all ages, with individuals under age 20 having a rate of 75%, while 78.2% of adults ≥20 years were seropositive. In addition, we also identified the presence neutralizing antibodies to VA1 from commercial lots of intravenous immunoglobulin (IVIG). Our results demonstrate that a majority of humans are exposed to VA1 by adulthood, with the majority of infections occurring between 2 and 9 years of age. In addition, our results indicate that VA1 has been circulating in two geographically and socioeconomically divergent study cohorts over the past 20 years. Nonetheless, a significant proportion of the human population lacks neutralizing immunity and remains at risk for acute infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.